Gleevec

Webcast Provides Perspective on Generic Imatinib

On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), originally for CML (Chronic Myeloid Leukemia), was approved by the FDA and became available for the first time in the United States through Sun Pharmaceuticals. In response to this transition, the LRG provided an educational Webinar to the CML and GIST communities on March 18th entitled “Generic Imatinib: Gaining Perspective.”

By |2020-07-09T15:58:49-04:00April 8th, 2016|Generics, GIST Education, Webcast|

Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]

By |2018-10-30T09:55:33-04:00March 15th, 2016|Drug Treatment, News, Survival Strategies|

The Heart of the Matter: Cardiac Health for GIST Patients

The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To [...]

By |2019-09-20T15:37:59-04:00February 10th, 2016|GIST Education, Newsletter, Side Effects|

Potential Treatment for Imatinib-Resistant GIST Explored

Dr. Ron DeMatteo GIST specialist surgeon Dr. Ron DeMatteo, along with colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC), has published a new paper in the April issue of Cancer Research with potentially [...]

By |2019-10-31T12:01:35-04:00June 16th, 2015|Drug Treatment, News, Research|

Importance of Therapeutic Drug Monitoring for Targeted Therapies

As personalized medicine has become an accepted paradigm, it may be time for oncologists to examine personalized dose levels.In a recent article from Cancer World, the author explores the value of therapeutic drug monitoring for [...]

By |2019-04-08T10:18:30-04:00May 1st, 2015|Drug Treatment, News|

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47-04:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|

Clinical Registry Study Planned by ASCO

American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR).  ASCO plans should increase patient access to off-label drugs and match patients with [...]

By |2018-07-06T13:59:34-04:00January 6th, 2015|Gleevec, News, Patient Support, Side Effects, Stivarga, Sutent|
Go to Top